Table 2 |
||||||
|
Summary of clinical response. |
||||||
|
Patient number |
Clinical outcome |
Time to complete response (weeks) |
Follow-up period (months) |
Maximun dose received (mg) |
Relapse |
Dose at relapse |
|
|
||||||
|
1 |
CR |
10 |
15 |
5 |
Yes |
5 mg twice weekly |
|
2 |
CR |
4 |
12 |
5 |
Yes |
5 mg three times weekly |
|
3 |
Withdrawn |
- |
- |
5 |
- |
- |
|
4 |
CR |
3 |
12 |
5 |
Yes |
5 mg alternate days |
|
5 |
CR |
36 |
19 |
5 |
- |
- |
|
6 |
CR |
4 |
17 |
5 |
No |
- |
|
7 |
CR |
11 |
18 |
5 |
No |
- |
|
8 |
CR |
2 |
7 |
5 |
Yes |
5 mg alternate days |
|
9 |
PR |
- |
15 |
10 |
- |
- |
|
10 |
CR |
7 |
10 |
5 |
Yes |
5 mg alternate days |
|
11 |
CR |
4 |
30 |
5 |
Yes |
5 mg twice weekly |
|
12 |
CR |
4 |
25 |
5 |
Yes |
5 mg alternate days |
|
13 |
PR |
- |
8 |
5 |
- |
- |
|
14 |
CR |
12 |
17 |
5 |
Yes |
5 mg three times weekly |
|
15 |
CR |
2 |
10 |
5 |
Yes |
5 mg alternate days |
|
|
||||||
|
CR, complete response; PR, partial response. |
||||||
|
Cortés-Hernández et al. Arthritis Research & Therapy 2012 14:R265 doi:10.1186/ar4111 |
||||||
